Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

SARS-CoV-2 sero-prevalence in the workforces of three large workplaces in South Wales: a sero-epidemiological study

View through CrossRef
Abstract BackgroundSero-prevalence studies quantify the proportion of a population that has antibodies against SARS-CoV-2, and can be used to identify the extent of the COVID-19 pandemic at a population level. The aim of the study was to assess the sero-prevalence of SARS-CoV-2 antibodies in the workforce at three workplaces. Methods993 participants were recruited from three workplaces in South Wales: a food factory, a non-food factory and a call centre. Participants completed a questionnaire and received lateral flow point-of-care SARS-CoV-2 antibody tests. The data were analysed using multivariable logistic regression, both using complete records only and following multiple imputation. ResultsThe sero-prevalence of SARS-CoV-2 antibodies ranged from 4% (n=17/402) in the non-food factory to 10% (n=28/281) in the food factory (OR 2.93; 95% CI 1.26 to 6.81). After taking account of confounding factors evidence of a difference remained (cOR comparing food factory to call centre (2.93; 95% CI 1.26 to 6.81) and non-food factory (3.99; 95% CI 1.97 to 8.08) respectively). The SARS-CoV-2 antibody prevalence also varied between roles within workplaces. People working in office based roles had a 2.23 times greater conditional odds (95% CI 1.02 to 4.87) of being positive for SARS-CoV-2 antibodies than those working on the factory floor.ConclusionThe sero-prevalence of SARS-CoV-2 antibodies varied by workplace and work role. Whilst it is not possible to state whether these differences are due to COVID-19 transmission within the workplaces, it highlights the importance of considering COVID-19 transmission in a range of workplaces and work roles.
Title: SARS-CoV-2 sero-prevalence in the workforces of three large workplaces in South Wales: a sero-epidemiological study
Description:
Abstract BackgroundSero-prevalence studies quantify the proportion of a population that has antibodies against SARS-CoV-2, and can be used to identify the extent of the COVID-19 pandemic at a population level.
The aim of the study was to assess the sero-prevalence of SARS-CoV-2 antibodies in the workforce at three workplaces.
Methods993 participants were recruited from three workplaces in South Wales: a food factory, a non-food factory and a call centre.
Participants completed a questionnaire and received lateral flow point-of-care SARS-CoV-2 antibody tests.
The data were analysed using multivariable logistic regression, both using complete records only and following multiple imputation.
ResultsThe sero-prevalence of SARS-CoV-2 antibodies ranged from 4% (n=17/402) in the non-food factory to 10% (n=28/281) in the food factory (OR 2.
93; 95% CI 1.
26 to 6.
81).
After taking account of confounding factors evidence of a difference remained (cOR comparing food factory to call centre (2.
93; 95% CI 1.
26 to 6.
81) and non-food factory (3.
99; 95% CI 1.
97 to 8.
08) respectively).
The SARS-CoV-2 antibody prevalence also varied between roles within workplaces.
People working in office based roles had a 2.
23 times greater conditional odds (95% CI 1.
02 to 4.
87) of being positive for SARS-CoV-2 antibodies than those working on the factory floor.
ConclusionThe sero-prevalence of SARS-CoV-2 antibodies varied by workplace and work role.
Whilst it is not possible to state whether these differences are due to COVID-19 transmission within the workplaces, it highlights the importance of considering COVID-19 transmission in a range of workplaces and work roles.

Related Results

The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract Introduction Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genes
AbstractBackgroundSevere acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is an emerging disease with fatal outcomes. In this study, a fundamental knowledge gap question is to...
Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays
Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays
ABSTRACTThe COVID-19 pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread worldwide. Serological testing for SARS-CoV-2-spe...
Analyses of the Spike Proteins of Severe Acute Respiratory Syndrome-Related Coronaviruses
Analyses of the Spike Proteins of Severe Acute Respiratory Syndrome-Related Coronaviruses
Aim: To analyze spike proteins of Severe Acute Respiratory Syndrome (SARS)-related coronaviruses (CoVs) for their conserved motifs, Receptor-Binding  Domain (RBD), Receptor Binding...
SARS-CoV-2 within-host diversity of human hosts and its implications for viral immune evasion
SARS-CoV-2 within-host diversity of human hosts and its implications for viral immune evasion
ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously evolving, bringing great challenges to the control of the virus. In the...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia
Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia
Abstract Background Anti-SARS-CoV-2 antibody tests are being increasingly used for sero-epidemiological purposes to provide bet...

Back to Top